ResearcherWashington University in St. LouisActive in the last 2 years
Brett H. Herzog
Matched on ORCID iD 0000-0001-6214-2926; OpenAlex author ID A5016663666; NIH RePORTER profile ID 10107513. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 1
- Labs led
- 1
- Collaborators
- 18
2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 grant
Papers 3
- Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansio… Co-author DOI 10.1158/1078-0432.ccr-23-2993↗
- Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Co-author DOI 10.1158/1078-0432.ccr-22-0308↗
- Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.02.008↗
Grants 1
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- William G. Hawkins · 3 shared papers, 2020–2023 · strength 0.33
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Paper Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. DOI 10.1016/j.ccell.2020.02.008↗
- David G DeNardo · 3 shared papers, 2020–2023 · strength 0.33
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Paper Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. DOI 10.1016/j.ccell.2020.02.008↗
- Jad I. Belle · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Feng Gao · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Benjamin R. Tan · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Katrina Sophia Pedersen · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Kian‐Huat Lim · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Albert Craig Lockhart · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Robert R. McWilliams · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Andrea Wang‐Gillam · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Julie Kristina Schwarz · 1 shared paper, 2020 · strength 0.09
- Varintra E. Lander · 1 shared paper, 2020 · strength 0.09
- Graham D. Hogg · 1 shared paper, 2020 · strength 0.09
- John M. Baer · 1 shared paper, 2020 · strength 0.09
- Samarth Hegde · 1 shared paper, 2020 · strength 0.09
- Carl DeSelm · 1 shared paper, 2020 · strength 0.09
- Chong Zuo · 1 shared paper, 2020 · strength 0.09
- Ryan C Fields · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.